Eloxatin, combined with the chemotherapy regimen of 5-FU/LV, is approved by the FDA for the treatment of advanced colorectal cancer (cancer of the colon and/or rectum).
Sanofi, under licensing agreement with Switzerland-based Debiopharm, markets Eloxatin. Sanofi has filed lawsuit against Par, along with other makers of generic versions of Eloxatin, in 2007 for patent infringement.
Under the settlement, Par is expected to begin selling its generic version of Eloxatin in August 2012, or earlier under certain circumstances.
The settlement agreements are subject to review by the Federal Trade Commission, the US Department of Justice, and the Attorney General for the State of Michigan.